Charles River guide to USP chapter 86 for bacterial endotoxin testing
 

Response Biomedical Receives FDA 510(k) Clearance of Rapid Influenza A+B Test

Response Biomedical Corporation has received FDA 510(k) clearance to market a rapid Influenza A+B test (Flu A+B test) and a new version of the RAMP® Reader, the RAMP® 200.

The test manufactured by Response Biomedical runs on the new RAMP® 200 Reader and will be marketed and sold worldwide exclusively by 3M Health Care as the 3M™ Rapid Detection Flu A+B Test. It is a qualitative immunochromatographic assay indicated for use as an in vitro diagnostic product with the 3M™ Rapid Detection Reader (manufactured by Response) to identify the presence of Flu A and Flu B nucleoprotein antigen in nasopharyngeal swab, nasopharyngeal aspirate, nasal wash/aspirate specimens.

Measurement of Flu A and Flu B aids in the rapid differential diagnosis of influenza viral infections through use of this test.

3M Health Care anticipates launching prior to the 2008-09 flu season in certain markets around the world.

NOTE: This item is from our 'historic' database and may contain information which is not up to date.

Source : Response Biomedical Corp. View Company Information

Posted on April 22, 2008



Puritan specimen collection devices are designed with people in mind
 

Pyrostar Neo plus recombinant endotoxin detection reagent from FUJIFILM
 

Woman smiling new products coming from MWE see us at ESCMID 2025
 

Bridging the Gap a rapidmicrobiology special focus
 

Get our eNewsletter
Over 7,000 microbiology professionals get our weekly eNewsletter - subscribe now and find out why!

LATEST MICROBIOLOGY NEWS

MICROBIOLOGY EVENTS